CTL with optimal effector function play critical roles in mediating protection against various intracellular infections and cancer. However, individuals may exhibit suppressive immune microenvironment and, in contrast to activating CTL, their autologous antigen presenting cells may tend to tolerize or anergize antigen specific CTL. As a result, although still in the experimental phase, CTL-based adoptive immunotherapy has evolved to become a promising treatment for various diseases such as cancer and virus infections. In initial experiments ex vivo expanded CMV (cytomegalovirus) specific CTL have been used for treatment of CMV infection in immunocompromised allogeneic bone marrow transplant patients. While it is common to have life-threatening CMV viremia in these patients, none of the patients receiving expanded CTL develop CMV related illness, implying the anti-CMV immunity is established by the adoptively transferred CTL While there are many ways to ex vivo stimulate and expand human CTL, current approaches are restricted by the cost and technical limitations. For example, the current gold standard is based on the use of autologous DC. This requires each patient to donate a significant number of leukocytes and is also very expensive and laborious. Moreover, detailed in vitro characterization of DC expanded CTL has revealed that these have only suboptimal effector function 3 .
1
. Promising results have also been observed for melanoma and may be extended to other types of cancer 2 
.
While there are many ways to ex vivo stimulate and expand human CTL, current approaches are restricted by the cost and technical limitations. For example, the current gold standard is based on the use of autologous DC. This requires each patient to donate a significant number of leukocytes and is also very expensive and laborious. Moreover, detailed in vitro characterization of DC expanded CTL has revealed that these have only suboptimal effector function 3 .
Here we present a highly efficient aAPC based system for ex vivo expansion of human CMV specific CTL for adoptive immunotherapy ( Figure  1 ). The aAPC were made by coupling cell sized magnetic beads with human HLA-A2-Ig dimer and anti-CD28mAb 4 . Once aAPC are made, they can be loaded with various peptides of interest, and remain functional for months. In this report, aAPC were loaded with a dominant peptide from CMV, pp65 (NLVPMVATV). After culturing purified human CD8 + CTL from a healthy donor with aAPC for one week, CMV specific CTL can be increased dramatically in specificity up to 98% ( Figure 2 ) and amplified more than 10,000 fold. If more CMV-specific CTL are required, further expansion can be easily achieved by repetitive stimulation with aAPC. Phenotypic and functional characterization shows these expanded cells have an effector-memory phenotype and make significant amounts of both TNFα and IFNγ ( Figure 3 ). The beads can be stored at 4°C and remain functional for at least 6 month.
Video Link
3. Human CTL isolation 
In vitro aAPC based culture system
1. Prepare culture medium 1. For TF (T cell growth factor, made in the lab 4 ) 2X culture medium: complete RPMI medium plus 5% donor autologous plasma and 8% T cell growth factor. 2. Donor autologous plasma can be substituted by heat-inactivated human AB serum.
2. Resuspend 1 million CTL in 8ml of TF 2X culture medium plus 8ml of complete RPMI medium, add 1×10 6 aAPC, mix well.
3. Use a multi-channel pipetter to plate cells onto 96 well U bottom tissue culture plates. (160 μl per well) 4. Culture cells in 37°C, 5% CO 2 incubater for 7 days. Feed the cells on day 4 with 80 μl/well TF 2X medium. 5. Cells are ready to be harvested on day 7. After harvest, place the cells against the magnet and remove the old aAPC. 6. Antigen specificity can be determined by tetramer staining according to manufacturer's protocol. Phenotype staining and intracellular cytokine staining are performed according to our previous study 3 . 7. Harvested cells can be replated with aAPC again under the same conditions. Cell number and antigen specificity is expected to increase after repeated stimulation.
Representative Results:
An example of aAPC after HLA A2-Ig and anti-CD28 conjugation is shown in Figure 4 . Successful protein conjugation is evident by a clear shift of corresponding antibody staining. While the frequency of CMV specific CTL in the peripheral blood is typically 0.5-1%, after a single week of aAPC-mediated stimulation, the specificity can reach 55-93% (Figure 2 and 3) . The expansion of antigen specific CTL can be very variable between different donors, but the results are reproducible within the same donor. By extrapolation, the expansion of CMV specific cells can be thousands of fold compared with precursor levels directly ex vivo (data not shown). Intracellular cytokine staining ( Figure 3 ) shows that these expanded CTL are polyfunctional, rather than exhausted, after prolonged cell culture and significant proliferation. 
Discussion
The aAPC system we describe here is an efficient system for ex vivo expansion of human CTL against a variety of antigens. Special care should be taken with regards to the quality of protein conjugation and the even distribution of aAPC and CTL in the 96-well plate culture. Using this approach we have been able to expand CTL for more than 8 weeks, during which we expanded antigen-specific CTL up to a million fold 4 . There have been various artificial APC systems utilizing cell lines or other acellular platforms 5 ; however, according to the published data every system has its unique profile with regards to expansion and specificity supporting different applications. Importantly, since the quality of CTL is as important as quantity, the polyfunctionality of the CMV-specific CTL generated by our system are expected to confer superior anti-viral efficiency.
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